Table of Contents

September 01, 2011; Volume 78, Issue 9
  • From the Editor

      • When to stop treating the bones

        Brian F. Mandell, MD, PhD
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 563;
        • DOI: https://doi.org/10.3949/ccjm.78b.11009
        • Don’t let the argument about how long to treat osteoporosis with bisphosphonate drugs stand in the way of initiating therapy in patients at risk of fracture.

  • Medical Grand Rounds

  • Review

      • Allergy blood testing: A practical guide for clinicians

        Roxana I. Siles, MD and Fred H. Hsieh, MD
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 585-592;
        • DOI: https://doi.org/10.3949/ccjm.78a.11023
        • These tests can confirm the diagnosis of an allergic disorder, supplementing the clinical history. They are particularly useful when skin testing cannot or should not be done.

  • The Clinical Picture

      • Oral plaques and dysphagia in a young man

        Amber S. Tully, MD and Carol Dao, MD
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 594-596;
        • DOI: https://doi.org/10.3949/ccjm.78a.10150
        • A 23-year-old man presents with oral plaques, a sore throat, dysphagia, malaise, and weight loss. What is the most likely diagnosis?

  • Review

  • The Clinical Picture

      • Unmasking gastric cancer

        Faysal Altahawi, Abdul Hamid Alraiyes, MD and M. Chadi Alraies, MD, FACP
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 606-608;
        • DOI: https://doi.org/10.3949/ccjm.78a.10129
        • Screening with diagnostic imaging may be justified in high-risk groups, although the issue is debatable.

  • Review

      • Venous thromboembolism: What to do after anticoagulation is started

        Scott Kaatz, DO, MSc, FACP, Waqas Qureshi, MD and Robert C. Lavender, MD, FACP
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 609-618;
        • DOI: https://doi.org/10.3949/ccjm.78a.10175
        • Three issues need to be addressed: the length of therapy, measures to prevent postthrombotic syndrome, and a basic workup for possible underlying malignancy.

  • Current Drug Therapy

      • TOC Icon

        What is the optimal duration of bisphosphonate therapy?

        Susan M. Ott, MD
        • Cleveland Clinic Journal of Medicine September 2011, 78 (9) 619-630;
        • DOI: https://doi.org/10.3949/ccjm.78a.11022
        • It is reasonable to stop bisphosphonates after 5 years of use and then to follow patients with markers of bone turnover.